|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0201405,
umls-concept:C0201734,
umls-concept:C0205179,
umls-concept:C0205314,
umls-concept:C0205390,
umls-concept:C0215136,
umls-concept:C0280100,
umls-concept:C0574032,
umls-concept:C0585333,
umls-concept:C0679622,
umls-concept:C1521801,
umls-concept:C1883567
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-1-16
|
|
pubmed:abstractText |
To assess the feasibility of administering XRP6258, a new taxane with a low affinity for the multidrug resistance 1 protein, as a 1-hour i.v. infusion every 3 weeks. The study also sought to determine the maximum tolerated dose and the recommended dose, to describe the pharmacokinetic (PK) behavior of the compound, and to seek preliminary evidence of anticancer activity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BeeramMuralidharM,
pubmed-author:BesenvalMichèleM,
pubmed-author:DebonoJohann SJS,
pubmed-author:DenisLouis JLJ,
pubmed-author:ForouzeshBahramB,
pubmed-author:GoetzAndrew DAD,
pubmed-author:MitaAlain CAC,
pubmed-author:MolpusKathleenK,
pubmed-author:OchoaLeonelL,
pubmed-author:PatnaikAmitaA,
pubmed-author:RowinskyEric KEK,
pubmed-author:SemiondDorothéeD,
pubmed-author:TolcherAnthony WAW
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
723-30
|
|
pubmed:meshHeading |
pubmed-meshheading:19147780-Adult,
pubmed-meshheading:19147780-Aged,
pubmed-meshheading:19147780-Aged, 80 and over,
pubmed-meshheading:19147780-Antineoplastic Agents,
pubmed-meshheading:19147780-Area Under Curve,
pubmed-meshheading:19147780-Female,
pubmed-meshheading:19147780-Humans,
pubmed-meshheading:19147780-Male,
pubmed-meshheading:19147780-Maximum Tolerated Dose,
pubmed-meshheading:19147780-Middle Aged,
pubmed-meshheading:19147780-Neoplasm Metastasis,
pubmed-meshheading:19147780-Neoplasms,
pubmed-meshheading:19147780-Neutropenia,
pubmed-meshheading:19147780-Taxoids
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
|
|
pubmed:affiliation |
Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
